avatrombopag
Selected indexed studies
- Avatrombopag. (, 2006) [PMID:34813255]
- Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. (Br J Haematol, 2018) [PMID:30191972]
- Avatrombopag: A Review in Thrombocytopenia. (Drugs, 2021) [PMID:34709601]
_Worker-drafted node — pending editorial review._
Connections
avatrombopag is a side effect of
Sources
- Avatrombopag. (2006) pubmed
- Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. (2018) pubmed
- Avatrombopag: A Review in Thrombocytopenia. (2021) pubmed
- Avatrombopag for the Treatment of Immune Thrombocytopenia. (2025) pubmed
- Avatrombopag in immune thrombocytopenia and beyond: Current evidence and emerging perspectives. (2025) pubmed
- Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI). (2024) pubmed
- Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. (2018) pubmed
- Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. (2022) pubmed
- Avatrombopag: First Global Approval. (2018) pubmed
- Avatrombopag for the treatment of immune thrombocytopenia. (2019) pubmed